Filament Health Corp. and ATMA Journey Centers announced the recent dosing of 14 healthy subjects with Filament's natural psilocybin drug candidate in a Health Canada-approved clinical trial as part of ATMA's psychedelic-assisted therapist training program. The trial's success reflects the operational calibre of both ATMA and Filament.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0377 USD | 0.00% | +4.72% | -30.31% |
1st Jan change | Capi. | |
---|---|---|
-30.31% | 7.96M | |
+7.67% | 219B | |
+7.75% | 187B | |
+11.47% | 134B | |
+26.84% | 101B | |
+0.30% | 62.27B | |
+16.30% | 52.82B | |
-1.63% | 47.49B | |
-1.59% | 40.79B | |
+11.95% | 39.35B |
- Stock Market
- Equities
- FLHLF Stock
- News Filament Health Corp.
- Filament Health Corp. and Atma Journey Centers Inc. Announce 14 Subjects Dosed in Health Canada-Approved Psilocybin Clinical Trial